Harvard Bioscience (NASDAQ:HBIO – Get Free Report) and Cytek Biosciences (NASDAQ:CTKB – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings.
Risk & Volatility
Harvard Bioscience has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.
Insider & Institutional Ownership
80.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 17.0% of Harvard Bioscience shares are held by insiders. Comparatively, 10.4% of Cytek Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Harvard Bioscience and Cytek Biosciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Harvard Bioscience | 1 | 3 | 1 | 0 | 2.00 |
| Cytek Biosciences | 1 | 1 | 2 | 0 | 2.25 |
Harvard Bioscience presently has a consensus price target of $6.75, indicating a potential downside of 28.12%. Cytek Biosciences has a consensus price target of $5.67, indicating a potential downside of 2.97%. Given Cytek Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Cytek Biosciences is more favorable than Harvard Bioscience.
Valuation and Earnings
This table compares Harvard Bioscience and Cytek Biosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Harvard Bioscience | $86.55 million | 0.50 | -$56.70 million | ($2.59) | -3.63 |
| Cytek Biosciences | $201.49 million | 3.79 | -$66.54 million | ($0.63) | -9.27 |
Harvard Bioscience has higher earnings, but lower revenue than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Harvard Bioscience and Cytek Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Harvard Bioscience | -13.20% | -43.94% | -5.15% |
| Cytek Biosciences | -39.10% | -13.13% | -9.56% |
Summary
Cytek Biosciences beats Harvard Bioscience on 7 of the 13 factors compared between the two stocks.
About Harvard Bioscience
Harvard Bioscience, Inc. develops, manufactures and sells scientific instruments and equipment used in life science research. Its products support work in areas such as physiology, electrophysiology and preclinical research, and are used by academic and government institutions, biotechnology and pharmaceutical companies, and contract research organizations. The company’s offerings include laboratory instruments, equipment and related consumables, including systems for measuring biological activity and studying tissues, organs and cells.
About Cytek Biosciences
Cytek Biosciences develops, manufactures and sells cell analysis instruments and related products used by researchers and clinical laboratories. Its systems use flow cytometry to analyze cells and other particles, supporting work in areas such as immunology, oncology and infectious disease research. The company’s product portfolio includes the Aurora and Northern Lights spectral flow cytometry systems and Amnis imaging flow cytometers. Cytek also offers reagents, software, technical support and other services that help customers prepare samples, collect and interpret data, and maintain their instruments.
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
